Azar, Trump Mislead on FDA’s Hydroxychloroquine Decision

At the White House, the Health and Human Services secretary left the misleading impression that the FDA's decision to revoke its emergency use authorization of hydroxychloroquine and chloroquine for COVID-19 “removes a potential barrier” and makes it easier to access the drugs. The FDA’s action does the opposite.

The post Azar, Trump Mislead on FDA’s Hydroxychloroquine Decision appeared first on FactCheck.org.